C. Gaich

2.6k total citations · 2 hit papers
40 papers, 1.9k citations indexed

About

C. Gaich is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, C. Gaich has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 18 papers in Hematology and 11 papers in Genetics. Recurrent topics in C. Gaich's work include Rheumatoid Arthritis Research and Therapies (34 papers), Autoimmune and Inflammatory Disorders Research (18 papers) and Systemic Lupus Erythematosus Research (13 papers). C. Gaich is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (34 papers), Autoimmune and Inflammatory Disorders Research (18 papers) and Systemic Lupus Erythematosus Research (13 papers). C. Gaich collaborates with scholars based in United States, United Kingdom and Canada. C. Gaich's co-authors include Terence Rooney, Stephanie de Bono, Douglas Schlichting, William L. Macias, Scott D. Beattie, Peter C. Taylor, Désirée van der Heijde, Yoshiya Tanaka, Edward Keystone and Vineet M. Arora and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

C. Gaich

38 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

2017 621 citations Peter C. Taylor, Edward Keystone et al. New England Journal of Medicine profile →
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Gaich United States	16	1.3k	662	459	444	360	40	1.9k
Jose L. Rivas Spain	11	852 0.7×	308 0.5×	306 0.7×	233 0.5×	206 0.6×	27	1.4k
Tim Shaw United States	9	1.3k 1.0×	463 0.7×	902 2.0×	272 0.6×	576 1.6×	16	2.5k
Jacques‐Eric Gottenberg France	20	961 0.7×	324 0.5×	328 0.7×	254 0.6×	248 0.7×	58	1.5k
Sergio Schwartzman United States	21	955 0.7×	398 0.6×	548 1.2×	98 0.2×	127 0.4×	59	1.4k
Joy Schechtman United States	11	1.1k 0.8×	421 0.6×	533 1.2×	146 0.3×	360 1.0×	17	1.7k
J S Smolen Austria	22	1.3k 1.0×	411 0.6×	614 1.3×	142 0.3×	116 0.3×	39	1.8k
Apostolos Kontzias United States	15	308 0.2×	379 0.6×	409 0.9×	355 0.8×	170 0.5×	31	1.3k
A. Gerards Netherlands	14	1.7k 1.3×	749 1.1×	336 0.7×	102 0.2×	383 1.1×	29	2.0k
Saeed Fatenejad United States	23	2.9k 2.2×	1.2k 1.8×	1.2k 2.5×	201 0.5×	479 1.3×	37	3.8k
M. Lange United States	6	1.7k 1.3×	941 1.4×	574 1.3×	181 0.4×	277 0.8×	7	2.2k

Countries citing papers authored by C. Gaich

Since Specialization

Citations

This map shows the geographic impact of C. Gaich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Gaich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Gaich more than expected).

Fields of papers citing papers by C. Gaich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Gaich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Gaich. The network helps show where C. Gaich may publish in the future.

Co-authorship network of co-authors of C. Gaich

This figure shows the co-authorship network connecting the top 25 collaborators of C. Gaich. A scholar is included among the top collaborators of C. Gaich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Gaich. C. Gaich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Yoshiya, Bruno Fautrel, Edward Keystone, et al.. (2019). Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 78(7). 890–898. 23 indexed citations

Michaud, Kaleb, Janet Pope, Paul Emery, et al.. (2019). Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatology and Therapy. 6(3). 409–419. 19 indexed citations

Bingham, Clifton O., C. Gaich, Amy M. DeLozier, et al.. (2019). Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. Trials. 20(1). 182–182. 27 indexed citations

Genovese, Mark C., Brett Hauber, W. Benjamin Nowell, et al.. (2019). Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatology and Therapy. 6(3). 461–471. 58 indexed citations

Fautrel, Bruno, Bruce Kirkham, Janet Pope, et al.. (2019). Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. Journal of Clinical Medicine. 8(9). 1394–1394. 38 indexed citations

Shi, Qiang, Ko‐Jen Li, Tamás Treuer, et al.. (2018). Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD). PLoS ONE. 13(4). e0193489–e0193489. 12 indexed citations

Katz, Patricia, Amanda Quebe, Hiren Patel, et al.. (2018). FRI0080 The role of pain in rheumatoid arthritis (RA) patients' assessments of their health. Annals of the Rheumatic Diseases. 77. 586–586.

Boytsov, Natalie, C. Gaich, Xiang Zhang, et al.. (2018). Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study. Rheumatology and Therapy. 5(1). 215–229. 4 indexed citations

Taylor, Peter C., R Fleischmann, Elizabeth L. Perkins, et al.. (2017). Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo. Oxford University Research Archive (ORA) (University of Oxford). 69. 1 indexed citations

10.

Bacci, Elizabeth D., Amy M. DeLozier, Chen‐Yen Lin, et al.. (2017). Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes. 15(1). 239–239. 11 indexed citations

11.

Taylor, Peter C., Edward Keystone, Désirée van der Heijde, et al.. (2017). Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal of Medicine. 376(7). 652–662. 621 indexed citations breakdown →

12.

Keystone, Edward, Peter C. Taylor, Yoshiya Tanaka, et al.. (2017). Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Annals of the Rheumatic Diseases. 76(11). 1853–1861. 83 indexed citations

13.

Schiff, Michael, Tsutomu Takeuchi, Roy Fleischmann, et al.. (2017). Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Research & Therapy. 19(1). 208–208. 51 indexed citations

14.

Bacci, Elizabeth D., Amy M. DeLozier, Chen‐Yen Lin, et al.. (2017). Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. Health and Quality of Life Outcomes. 15(1). 237–237. 2 indexed citations

15.

Dougados, Maxime, Désirée van der Heijde, Ying‐Chou Chen, et al.. (2016). Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases. 76(1). 88–95. 301 indexed citations breakdown →

16.

Smolen, Josef S, Joel M. Kremer, C. Gaich, et al.. (2016). Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Annals of the Rheumatic Diseases. 76(4). 694–700. 84 indexed citations

17.

Taylor, Peter C., E C Keystone, D. van der Heijde, et al.. (2015). Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Data Archiving and Networked Services (DANS). 67. 8–8. 15 indexed citations

18.

Gaich, C., et al.. (2015). Content Validity Evaluation of A New Diary Developed to Evaluate Symptoms Important to Patients With Moderate to Severe Rheumatoid Arthritis. Value in Health. 18(3). A165–A165. 2 indexed citations

19.

Smolen, Josef S, D. Schlichting, K.L. Sterling, et al.. (2012). 12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Arthritis & Rheumatism. 64. 5 indexed citations

20.

Recker, Robert R., David L. Kendler, Christopher Recknor, et al.. (2006). Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 40(4). 843–851. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact